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ABSTRACT
Objective: In this preliminary presentation the outcome of women following systemic treatment of
cervical human papilloma virus (HPV) with a leukocyte ultrafiltrate is reported.
Methods: Cervical brush specimens of 819 women with low-grade CIN-1 were evaluated for
HPV infection. HPV-positive patients were treated either by cone biopsy because of suspicious
eolposeopy or by antibiotics for symptoms of bacterial cervieitis. The remaining women were
considered as asymptomatic carriers ofHPV and underwent systemic therapy by a human leuko-
cyte ultrafiltrate in a dosage of 5 IE, 6 times in the first 2 weeks, and additionally as a single dose
at weeks 4, 6, 8 and 10.
Results: The leukocyte ultrafiltrate was administered to 97 HPV-positive women. In follow-up
88.7% were HPV negative at week 6; the remaining 11 women were tested negative after comple-
tion of a second course of therapy.
Conclusions: These preliminary data on the successful treatment ofHPV infection by a leukocyte
ultrafiltrate are very promising but have to be supported by additional research. Infect. Dis. Obstet.
Gynecol. 8:120-123, 2000. (C) 2000 Wiley-L’iss, Inc.
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of HPV in our population is esti-
mated to be as high as 10% in women in the
reproductive age, but significantly higher in symp-
tomatic patients. In the past decade convincing
data on the relationship of human papilloma virus
(HPV) infection to cervical neoplasia have been
published.
About 30 of more than 100 serotypes appear to
be relevant in this respect. HPV detection seems to
be associated with at least a 10 times greater risk of
cervical neoplasia. 1,z Lorincz et al.3 defined the fol-
lowing categories for the associated risk ofcommon
anogenital types:
1. low risk (HPV 6/11, 42, 43, 44)
2. intermediate risk (HPV 31, 33, 35, 51, 52, 58)
3. high risk/HPV 16
4. high risk/HPV 18.
The presence of oncogenic HPV conferred rela-
tive risks in the range of 65.1-235.7 for the occur-
rence of a high-grade lesion and 31.1-296.1 for an
invasive cancer. However, an intermediate or high
amount of HPV 16 DNA predicted the presence of
high-grade CIN in a subsequent biopsy in almost
90% of patients, irrespective of the cytological
grade of the referral smear.4 According to De Vil-
liers et al.s the progression of HPV-positive women
from normal cytology to CIN, or cancer, occurred at
an annual frequency of 0.082%. With an assumed
infected life span of 45 years, the lifetime risk is
3.7%. On the other hand, in another study by
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Nuovo et al.,6 most women showed no evidence of
squamous intraepithelial lesions on follow-up if the
concurrent Pap smear was normal, even when
HPV-DNA was detected. This suggests that HPV
detection per se does not necessarily correlate with
subsequent squamous intraepithelial lesion. In ad-
dition, coexistent active cervical infections (e.g.,
chlamydial infection) seem to have no influence on
the clinical course of HPV lesions, as reported by
Yliskoski et al.,7 but suppression of local immunity
may be important.
Topical podophyllin and surgery have been
used for years in the routine treatment of condylo-
mata acuminata and HPV infection, respectively,
but podophyllotoxin, interferon, and imiquimod
are alternatives under serious consideration. Von
Krogh and Hellberg8 reported a complete and per
manent cure with 0.5% podophyllotoxin cream in
77% of their study group (34 out of 44 patients).
Stellato9 achieved a complete response of33% (8 of
24 women) in their study group and a partial re-
gression one year after treatment of 58% (14 of 24
women) with recombinant 2b interferon adminis-
tered by intra-/perilesional injection. Edwards et
al.1 reported a 72% success rate in women with
condylomata acuminata following treatment With
5% imiquimod cream, however, most reports about
these latter regimen lack data concerning cervical
HPV infection.
Considering the high prevalence of HPV infec-
tion, its infectious and oncogenic potential, as well
as the poor treatment results, a great deal of inter-
est is directed towards the evaluation of alternative
therapies. In this preliminary investigation the out-
come of women following systemic treatment of
cervical HPV with a leukocyte ultrafiltrate is re-
ported.
MATERIALS AND METHODS
Cervical brush specimen of 819 women with low-
grade CIN-1 were evaluated by means of in situ-
hybridization (Biohit, Helsinki, Finland) and poly-
merase chain reaction (PCR) (biotin marked
primer, provided by A. Stelzner, University ofJena,
Germany) for HPV infection at the Department of
Obstetrics and Gynaecology, Klinikum Erfurt.
HPV-positive patients were treated either by cone
biopsy because of suspicious colposcopy (e.g.,
punctated acetic white lesions) or by antibiotics for
clinical symptoms of bacterial cervicitis. The re-
TABLE I. Prevalence of selected HPV types in
273 patients
HPV type Percent (%)
6 58.6
II 65.2
16 84.3
18 81.0
31 31.5
32 16.9
maining women were considered as asymptomatic
carriers of HPV and underwent systemic therapy
by a commercially available human leukocyte ul-
trafiltrat (LeukoNorm Cyto-Chemia (R), Ihringen,
Germany) of patented, but not stated composition
in a nonrandomized prospective fashion.
The inclusion criteria were as follows:
nonbacterial chronic cervicitis, HPV 16/18 posi-
tive,
low-grade CIN-1 (koilocytosis facultative), HPV
16/18 positive,
colposcopic signs of HPV-infection, HPV 16/18
positive, and
age >- 18 years, informed consent.
Women with histological proven carcinoma,
CIN-2 or CIN-3, other untreated infections, or
pregnancy were excluded from the treatment trial.
The leukocyte ultrafiltrate was suspended in a
5-ml isotonic NaC1 solution and administered in-
tramuscularly (M. gluteus maximus) in a dosage of
5 IE (I.E. Internationale Einheit, International
Unit), six times in the first two weeks and addi-
tionally as a single dose at weeks 4 and 6 and if
indicated because of HPV persistence at weeks 8
and 10.
All women were evaluated by PCR for HPV at
week 6 and if still positive at week 10. In women
testing positive at week 10, a second course of
therapy was administered (10 doses of 5 IE 2 weeks
apart). Complete long-term follow-up was not pos-
sible for technical reasons.
RESULTS
A total of 33.3% of all women investigated (273/
819) were found to be HPV positive. A total of 921
different strains of HPV were found, at least two in
each of the patients (Table 1).
Therapy of the HPV-positive patients was as
follows: 49 (17.9%) underwent cone biopsy and 127
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(46.5%) were treated for cervicitis by antibiotics.
The leukocyte ultrafiltrate was administered to 97
(35.5%) HPV-positive women (mean age 27.0
years).
In follow-up 86 of the 97 patients who received
leukocyte ultrafiltrate (88.7%) were HPV negative
at week 6; the remaining 11 women tested negative
after completion of therapy at week 30. All women
were asymptomatic following treatment. Adverse
reactions possibly due to the leukocyte preparation
were not observed.
DISCUSSION
Convincing data in the literature support the hy-
pothesis that cervical lesions referred to as CIN
comprise two distinct and histologically separable
entities: low-grade CIN-1 with HPV types 16, 18,
or 33, in less than 30% of cases, and high-grade
CIN-2 and CIN-3 associated with these types in
almost 90% of cases. The high oncogenic risk types
16, 18, or 33 were detected in 29% of 100 cases with
CIN-1 and in 88% of 176 cases with CIN-2 or CIN-
3.11 To put the reported findings into practice it
appears efficient, at present, to re-evaluate patients
with oncogenic HPV types in association with low-
grade cytology, as well as women with high-grade
cytology or suspicious colposcopy at frequent inter-
vals.
The management of women with low-grade or
borderline cytology is still unsettled. An efficient
therapy for HPV infection would be promising,
since it is likely that it would be able to reduce the
risk of subsequent carcinoma. However, other con-
tributing risk factors such as smoking, drugs, pro-
miscuity, immunosuppression or incompetence,
and chronic diseases also have to be taken into
account.
In our study we used a leukocyte ultrafiltrate
that is supposed to induce an immunological re-
sponse by means of ribonucleopeptides of still un-
known structure. The mechanism is thought to be
enhanced by immunological stimulation of prolif-
eration and maturation of T-lymphocytes as well as
by stimulation of lymphokines, lz The same mode
of action has been applied successfully in treat-
ment of chronic infections in general medicine.
These preliminary data on the successful treat-
ment of HPV infection by a leukocyte ultrafiltrate
have to be supported by additional research focus-
ing on two topics: (1) What is the mode of action of
this immunomodulating (ribonucleopeptide) sub-
stance and (2) is the surprisingly high cure rate
reproducible and long lasting in a randomized,
double-blinded prospective study?
Until now the leukocyte ultrafiltrate is regis-
tered in Germany for primary and secondary im-
munodeficiencie and for immunocompromised
hosts suffering from viral infections. Treatment of
HPV infection by leukocyte ultrafiltrate, however,
is still experimental and rather expensive (phar-
macy costs about $3500/case, so the indication for
therapy is limited and to be defined with caution.
From our experience with patients suffering from
persistent HPV infections, we can recommend im-
munotherapy as trial for the following cases:
young fertile women with a desire for children,
reliable in cytological control, and no indication
for cone biopsy
persistent HPV infection with type 16/18, espe-
cially with remaining koilocytosis after cone bi-
opsy or laser treatment, or
chronic HPV infection with recurrent suspicious
cytology (also in pregnancy?).
However, in the current stage of research, the
use of the leukocyte ultrafiltrate investigated has to
be limited to proven low-grade CIN-1 in order not
to postpone adequate therapy of possible carci-
noma.
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